Compare Stocks: QTRX, SIBN, DNA, and PACB

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DNA Ginkgo Bioworks	$6.98 -3.9%	$8.37	$5.37 ▼ $17.58	$468.69M	1.78	1.29 million shs	1.26 million shs
PACB Pacific Biosciences of California	$1.40 -9.7%	$1.42	$1.07 ▼ $2.73	$435.16M	2.31	7.81 million shs	5.22 million shs
QTRX Quanterix	$2.64	$3.56	$2.15 ▼ $8.77	$124.85M	1.07	863,174 shs	349,489 shs
SIBN SiBone	$19.21 +0.1%	$17.87	$11.48 ▼ $21.89	$851.95M	0.66	551,973 shs	361,044 shs

10 Best Stocks to Own - Summer 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DNA Ginkgo Bioworks	0.00%	-5.16%	-14.20%	-25.55%	-43.82%
PACB Pacific Biosciences of California	0.00%	+3.70%	-5.41%	-6.04%	+5.26%
QTRX Quanterix	0.00%	-11.71%	-25.00%	-13.73%	-42.73%
SIBN SiBone	0.00%	-3.76%	+6.78%	+36.24%	+15.79%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DNA Ginkgo Bioworks	$6.98 -3.9%	$8.37	$5.37 ▼ $17.58	$468.69M	1.78	1.29 million shs	1.26 million shs
PACB Pacific Biosciences of California	$1.40 -9.7%	$1.42	$1.07 ▼ $2.73	$435.16M	2.31	7.81 million shs	5.22 million shs
QTRX Quanterix	$2.64	$3.56	$2.15 ▼ $8.77	$124.85M	1.07	863,174 shs	349,489 shs
SIBN SiBone	$19.21 +0.1%	$17.87	$11.48 ▼ $21.89	$851.95M	0.66	551,973 shs	361,044 shs

10 Best Stocks to Own - Summer 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DNA Ginkgo Bioworks	0.00%	-5.16%	-14.20%	-25.55%	-43.82%
PACB Pacific Biosciences of California	0.00%	+3.70%	-5.41%	-6.04%	+5.26%
QTRX Quanterix	0.00%	-11.71%	-25.00%	-13.73%	-42.73%
SIBN SiBone	0.00%	-3.76%	+6.78%	+36.24%	+15.79%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DNA Ginkgo Bioworks	1.50	Reduce	$7.00	0.29% Upside
PACB Pacific Biosciences of California	1.80	Reduce	$1.83	30.95% Upside
QTRX Quanterix	1.67	Reduce	$3.00	13.64% Upside
SIBN SiBone	2.71	Moderate Buy	$24.17	25.80% Upside

Current Analyst Ratings Breakdown

Latest QTRX, SIBN, DNA, and PACB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/25/2026	PACB Pacific Biosciences of California	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/20/2026	SIBN SiBone	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/17/2026	DNA Ginkgo Bioworks	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
8/17/2026	QTRX Quanterix	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Hold	$4.00 ➝ $3.00
8/11/2026	PACB Pacific Biosciences of California	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/11/2026	QTRX Quanterix	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Hold	$4.00 ➝ $3.00
8/7/2026	QTRX Quanterix	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/7/2026	DNA Ginkgo Bioworks	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold	$12.00 ➝ $9.00
8/5/2026	SIBN SiBone	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/4/2026	SIBN SiBone	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$24.00 ➝ $25.00
8/4/2026	SIBN SiBone	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$18.00 ➝ $20.00

(Data available from 8/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DNA Ginkgo Bioworks	$170.15M	2.76	N/A	N/A	$8.74 per share	0.80
PACB Pacific Biosciences of California	$160.01M	2.72	$0.79 per share	1.77	$0.02 per share	70.00
QTRX Quanterix	$138.90M	0.90	N/A	N/A	$6.33 per share	0.42
SIBN SiBone	$200.93M	4.24	N/A	N/A	$4.09 per share	4.70

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DNA Ginkgo Bioworks	-$312.76M	-$5.01	N/A	N/A	N/A	-259.96%	-60.27%	-26.88%	11/5/2026 (Estimated)
PACB Pacific Biosciences of California	-$546.38M	-$0.43	N/A	N/A	N/A	-82.49%	-5,752.12%	-19.52%	11/3/2026 (Estimated)
QTRX Quanterix	-$107.15M	-$2.63	N/A	N/A	N/A	-80.25%	-26.09%	-19.03%	11/9/2026 (Estimated)
SIBN SiBone	-$18.90M	-$0.34	N/A	N/A	N/A	-6.85%	-8.23%	-6.07%	11/9/2026 (Estimated)

Latest QTRX, SIBN, DNA, and PACB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	QTRX Quanterix	-$0.4103	-$1.04	-$0.6297	-$1.04	$37.48 million	$32.91 million
8/5/2026	Q2 2026	DNA Ginkgo Bioworks	-$0.8950	-$0.75	+$0.1450	-$0.75	$24.05 million	$20.16 million
8/3/2026	Q2 2026	PACB Pacific Biosciences of California	-$0.1280	-$0.14	-$0.0120	-$0.14	$42.90 million	$39.01 million
8/3/2026	Q2 2026	SIBN SiBone	-$0.1495	-$0.09	+$0.0595	-$0.09	$55.34 million	$56.01 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
DNA Ginkgo Bioworks	N/A	N/A	N/A	N/A	N/A
PACB Pacific Biosciences of California	N/A	N/A	N/A	N/A	N/A
QTRX Quanterix	N/A	N/A	N/A	N/A	N/A
SIBN SiBone	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DNA Ginkgo Bioworks	N/A	4.57	4.57
PACB Pacific Biosciences of California	N/A	4.92	4.03
QTRX Quanterix	N/A	3.40	2.45
SIBN SiBone	0.20	9.15	7.55

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DNA Ginkgo Bioworks	78.63%
PACB Pacific Biosciences of California	N/A
QTRX Quanterix	86.48%
SIBN SiBone	98.11%

Insider Ownership

Company	Insider Ownership
DNA Ginkgo Bioworks	12.69%
PACB Pacific Biosciences of California	3.70%
QTRX Quanterix	1.50%
SIBN SiBone	4.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DNA Ginkgo Bioworks	640	67.34 million	58.80 million	Optionable
PACB Pacific Biosciences of California	730	310.83 million	299.33 million	Optionable
QTRX Quanterix	460	47.29 million	46.58 million	Optionable
SIBN SiBone	350	44.35 million	42.58 million	Optionable

QTRX, SIBN, DNA, and PACB Headlines

Recent News About These Companies

Anshul Maheshwari Sells 11,636 Shares of SiBone (NASDAQ:SIBN) Stock

August 27 at 7:07 AM | insidertrades.com

SiBone (NASDAQ:SIBN) Insider Anshul Maheshwari Sells 11,636 Shares of Stock

August 26, 2026 | marketbeat.com

SiBone (NASDAQ:SIBN) CEO Sells $522,556.64 in Stock

August 26, 2026 | marketbeat.com

Si-Bone (SIBN) is a Great Momentum Stock: Should You Buy?

August 25, 2026 | zacks.com

Wall Street Analysts Believe Si-Bone (SIBN) Could Rally 25.25%: Here's is How to Trade

August 24, 2026 | zacks.com

SiBone (NASDAQ:SIBN) CEO Sells 3,923 Shares of Stock

August 22, 2026 | insidertrades.com

Insider Selling: SiBone (NASDAQ:SIBN) CEO Sells 3,923 Shares of Stock

August 21, 2026 | marketbeat.com

SiBone (NASDAQ:SIBN) Insider Sells $112,353.85 in Stock

August 21, 2026 | marketbeat.com

Anshul Maheshwari Sells 11,228 Shares of SiBone (NASDAQ:SIBN) Stock

August 21, 2026 | marketbeat.com

SiBone (NASDAQ:SIBN) CEO Laura Francis Sells 51,884 Shares of Stock

August 21, 2026 | marketbeat.com

Michael Pisetsky Sells 3,725 Shares of SiBone (NASDAQ:SIBN) Stock

August 19, 2026 | insidertrades.com

SiBone (NASDAQ:SIBN) SVP Michael Pisetsky Sells 3,725 Shares of Stock

August 18, 2026 | marketbeat.com

Anshul Maheshwari Sells 4,665 Shares of SiBone (NASDAQ:SIBN) Stock

August 18, 2026 | marketbeat.com

SiBone $SIBN Shares Bought by Dimensional Fund Advisors LP

August 11, 2026 | marketbeat.com

SiBone (NASDAQ:SIBN) Receives Consensus Rating of "Moderate Buy" from Analysts

August 9, 2026 | marketbeat.com

SiBone $SIBN Shares Purchased by Sei Investments Co.

August 7, 2026 | marketbeat.com

Does Si-Bone (SIBN) Have the Potential to Rally 38.58% as Wall Street Analysts Expect?

August 6, 2026 | zacks.com

Insider Selling: SiBone (NASDAQ:SIBN) Director Sells $369,200.00 in Stock

August 6, 2026 | insidertrades.com

Renaissance Technologies LLC Increases Stake in SiBone $SIBN

August 6, 2026 | marketbeat.com

SiBone (NASDAQ:SIBN) Director Jeffrey Dunn Sells 20,000 Shares

August 5, 2026 | marketbeat.com

SiBone's (SIBN) Buy Rating Reaffirmed at Truist Financial

August 4, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

QTRX, SIBN, DNA, and PACB Company Descriptions

Ginkgo Bioworks NYSE:DNA

$6.98 -0.28 (-3.86%)

As of 08/28/2026 03:58 PM Eastern

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Pacific Biosciences of California NASDAQ:PACB

$1.40 -0.15 (-9.68%)

As of 08/28/2026 04:00 PM Eastern

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

Quanterix NASDAQ:QTRX

$2.64 0.00 (0.00%)

As of 08/28/2026 04:00 PM Eastern

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, it offers contract research services, including sample testing, homebrew assay development, custom assay development, lucent diagnostic, and LDT testing services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.

SiBone NASDAQ:SIBN

$19.21 +0.01 (+0.05%)

As of 08/28/2026 04:00 PM Eastern

SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest QTRX, SIBN, DNA, and PACB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest QTRX, SIBN, DNA, and PACB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

QTRX, SIBN, DNA, and PACB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

QTRX, SIBN, DNA, and PACB Company Descriptions

Ginkgo Bioworks NYSE:DNA

Pacific Biosciences of California NASDAQ:PACB

Quanterix NASDAQ:QTRX

SiBone NASDAQ:SIBN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest QTRX, SIBN, DNA, and PACB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest QTRX, SIBN, DNA, and PACB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

QTRX, SIBN, DNA, and PACB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

QTRX, SIBN, DNA, and PACB Company Descriptions

Ginkgo Bioworks NYSE:DNA

Pacific Biosciences of California NASDAQ:PACB

Quanterix NASDAQ:QTRX

SiBone NASDAQ:SIBN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools